Prognostic value of c-Met in colorectal cancer: A meta-analysis

Table 1 Characteristics of the selected studies

Ref.	No. of patients	Country	Method tostratify c-Metstatus	Stage	Stage(I, II)	High c-Metexpression	Survival	HR	95%CI
Zeng et al[17], 2008	247	United States	RT-qPCR	I-IV	46%	29%	OS	2.081	0.94-4.62
Voutsina et al[11], 2012	73	Greece	IHC	IV	NS	52%	OS	4.59	2.05-10.28
Resnick et al[19], 2004	134	Israel	IHC	I-IV	NS	77%	PFS	0.811	0.24-3.75
Garouniati et al[12], 2012	183	Greece	IHC	I-IV	61%	72%	OS	1.021	0.52-1.99
Inno et al[13], 2011	73	Italy	IHC	IV	NS	75%	PFS/OS	2.17/1.92	0.99-4.76/0.81-4.54
De Oliveira et al[14], 2009	286	Brazil	IHC	I-IV	53%	79%	PFS/OS	1.651/1.211	0.56-4.21/0.85-2.06
Kishiki et al[10], 2014	75	Japan	IHC	I-IV	NS	48%	PFS/OS	1.46/1.16	1.06-2.02/0.73-1.82
Ginty et al[16], 2008	583	United States	IHC	I-IV	46%	62%	OS	1.45	1.06-1.96
Kammula et al[18], 2006	63	United States	RT-qPCR	I-IV	39%	81%	OS	2.44	1.05-5.68
Lee et al[15], 2007	135	Taiwan	IHC	I-IV	NS	72%	PFS/OS	10.05/3.93	2.54-43.84/1.40-10.99
Umeki et al[20], 1999	43	Japan	IHC/RT-qPCR	I-IV	35%	30%/12%	OS	1.141	0.78-3.45

¹HR estimated, if the HRs were not directly given in the studies, we calculated them from the survival curves. RT-qPCR: Reverse transcriptase quantitative polymerase chain reaction; IHC: Immunohistochemistry; NS: Not shown.